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ABSTRACT 
Little is known about risk factors for emergency department (ED) attendance for 
chronic pain (CP) management and the relative service burden.  We examined emergency 
department (ED) utilisation in patients with chronic pain (CP), identified risk factors 
associated with attendance for chronic musculoskeletal pain (CMP) and estimated the 
comparative cost of treatment.  The study cohort comprised a random sample of 3,700 adults 
from the general population in Tayside, Scotland.  Linked regional extracts, spanning a 12-
month period, were obtained from national registers, providing information on ED 
attendances, community-dispensed prescribing and outpatient clinic attendances.  The NHS 
Scotland Cost Book was used to ascertain the current average cost of an ED attendance 
(£130; ~$167). 
All-cause ED attendance was higher in those with CP (68.5%; n=252) than without 
(29.3%; n=967).  In the entire cohort, more patients attended the ED for the treatment of 
CMP than for any other medical condition (n=119; 32.3% of those with CP).  Risk factors for 
ED attendance for CMP were: recent analgesic dose decreases (OR=4.55); and transitioning 
from opioid to non-opioid analgesics (OR=5.08).  Characteristics protective of ED attendance 
for CMP were: being in receipt of strong opioids (OR=0.21); transitioning from non-opioid to 
opioid analgesics (OR=0.25); recent analgesic dose increases (OR=0.24); and being 
prescribed tricyclic antidepressants (OR=0.10), benzodiazepines (OR=0.46) or hypnotics 
(OR=0.45).  CMP was one of the most expensive conditions to treat (£17,680 (~$22,668) per 
annum), conferring a substantial burden on ED services.  Improved understanding of the 
risk/protective factors could inform healthcare redesign to reduce avoidable ED attendances 
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Examination of the clinical factors associated with attendance at emergency 
departments for chronic pain management and the cost of treatment relative to that of 
other significant medical conditions 
 
INTRODUCTION 
Emergency departments (EDs) internationally are under constant pressure to meet 
increasing demand [711,2131,2434,2738,2839,3449,3752].  A proportion of patients may 
represent potentially avoidable demand, such as some of those attending for chronic pain 
(CP) management.  Indeed, many ED attendances for chronic diseases are reported to be 
preventable [5979].  Furthermore, the ED is not considered to be an appropriate setting for 
the management of CP [24,5270,6181,6282], and ED staff feel undertrained in treating this 
problem [85].  In order to better manage health services and treat patients more effectively, it 
is important to quantify the scale of this issue and understand the risk factors associated with 
ED attendance for the management of CP. 
CP is defined as pain that persists beyond that of normal tissue healing time, usually 
considered to be 3 months [2940].  A systematic review of UK prevalence studies of CP 
[1625] reported a pooled prevalence estimate of 43.5% (95% CI 38.4% - 48.6%).  CP ‘flare-
ups’ are common, reported to occur in up to three quarters of patients with chronic non-
cancer pain (CNCP) [4462].  CP accounts for 10-16% of all ED attendances in the USA 
[36,5270] with some individuals being heavily reliant on emergency service resources 
[5371,6181].  However, comparative UK figures are not currently available.  Effective 
community-based pain management, with continuity of care, may help to reduce the pressure 
on emergency services whilst providing more stable pain management for patients.  Indeed, a 
number of systematic reviews have reported the effectiveness of self-management techniques 





































































Very few studies have examined ED attendance for the management of CP.  The 
precise nature of data collection in EDs in Scotland does not currently allow identification of 
all patients attending for CP management.  Surrogate measures may potentially be used, such 
as recording of attendance for painful musculoskeletal conditions (excluding injury) among 
those identified with CP.  The Global Burden of Disease (GBD) 2017 Study showed that 
painful musculoskeletal conditions are the highest contributor to global disability and that 
low back pain has remained the single leading cause of disability since the first GBD Study in 
1990 [2333].  Indeed, one in two adult Americans are reported to live with a painful 
musculoskeletal condition, a prevalence comparable to that of cardiovascular and chronic 
respiratory diseases combined, totalling a cost of $213 billion in 2011, or 1.4% of gross 
domestic product [5472].  Painful musculoskeletal conditions are reported to consume almost 
a tenth of the UK’s National Health Service (NHS) budget, making this one of the most 
expensive specialties, after psychiatric disorders and cardiac disease [4563].  The present 
study aimed to: 
1) Quantify the proportion of those identified with CP who attended the ED for any reason 
within a 12-month period and, specifically, those who attended for the treatment of CMP; 
2) Characterise prescribed analgesic treatment in those identified with CP who attended the 
ED for any reason compared with those with chronic pain who did not attend the ED; 
3) Identify the clinical factors associated with ED attendance for CMP; 
4) Estimate ED resource utilisation associated with CP management compared with other 
significant medical conditions. 
 
METHODS 




































































The study cohort comprised a random sample of 3,700 adults from the general 
population in the NHS Tayside Health Board area, drawn from the 2014 database of all 
individuals registered with a general practitioner (GP) in NHS Tayside.  Each individual 
registered with a GP (>95% of the UK population) is assigned an NHS Community Health 
Index (CHI) number, a unique personal identifier that is contained within the medical records 
associated with all NHS events.  This identifier was used to achieve record linkage and 
pseudo-anonymisation, as described below.  The sample was generated by Health Informatics 
Centre (HIC) Services, Farr Institute, University of Dundee, using algorithms based on 
random number generation.  All Scottish NHS services, including general practitioner 
services, are delivered free at the point of contact to all patients, and this includes the 
dispensing of prescribed medication. 
 
Data sources 
Regional data extracts were obtained from several national Scottish health registers, 
which are held by the Information Services Division (ISD) of National Services Scotland 
(NSS) and were accessed by HIC Services.  The Accident & Emergency Datamart provides a 
record of all ED attendances and contains information on admission, diagnoses, treatment and 
discharge.  The Prescribing Information System (PIS) is a dataset that contains information 
on the drugs, dosages and instructions for all community-dispensed prescriptions.  The 
Scottish Morbidity Register (SMR) 00 contains a record of all NHS outpatient clinic 
attendances by specialty.  The SMR06 is a register of all patients diagnosed with malignant 
disease.  Demographic data were provided by HIC Services, from the NHS CHI dataset.  
These data comprised: gender; age; socioeconomic status using the Scottish Index of Multiple 
Deprivation (SIMD) quintiles (https://www.gov.scot/collections/scottish-index-of-multiple-





































































classification-2005-2006/pages/8/).  In accordance with SIMD recommendations, quintiles 1-
2 were used to indicate relative socioeconomic deprivation and quintiles 3-5 were used to 
indicate relative socioeconomic affluence.  Scottish Health Service Costs (commonly referred 
to as the ‘Cost Book’) was used to ascertain the average cost of each ED attendance, which 
falls at £130 (~$167).  This unit cost is consistent with the unit cost used in previous UK-
based studies, accounting for inflation [14,21,24,26,59].  Whilst the data used in the present 
study were collected in 2014, most recently-published Cost Book prices were used in 
calculating ED costs for each participant to allow a current understanding of the findings 
presented here.  The most recent Cost Book (2017) for each specialty can be found at 
http://www.isdscotland.org/Health-Topics/Finance/Costs/A-Z-Index/, where ED costs by 
health board can be found in Table R044X. 
 
Procedure 
Data were extracted from each of the datasets spanning a 12-month period for each 
participant (i.e. the 2014 calendar year).  All data were linked electronically within a secure 
virtual environment and anonymised prior to release to the research team via a Scottish 
Government-certified Safe Haven (Health Informatics Centre (HIC) Services, University of 
Dundee). 
We used prescribing records to identify people likely to have chronic pain.  
Participants were identified as having ‘chronic pain’ if they had been in receipt of 
prescription analgesics for at least three consecutive months during the observation period.  
Participants identified as having ‘acute pain’ (receipt of analgesic treatment for less than 
three consecutive months within the observation period) were excluded from the present 




































































National Formulary (BNF) codes (http://gmmmg.nhs.uk/html/formulary_bnf_chapters.html) 
used to indicate intention to treat, and these codes were used to identify participants who had 
been in receipt of analgesic prescriptions.  This field was used to ensure that the therapeutic 
indication was ascertained for medication that could be used for multiple purposes; for 
example, the use of antidepressants or anticonvulsants in the treatment of pain.  Individuals 
were included in the study where analgesia was indicated as the therapeutic intention for 
prescribing, and individuals were excluded where the indicated therapeutic intention was 
other than analgesia.  The BNF codes used to identify participants with chronic pain are 
shown in the supplementary digital content (Table S1). 
Malignant disease was identified through inclusion within the SMR06 and/or 
attendance at outpatient palliative care services (SMR00).  The presence of opioid 
dependence was identified using BNF codes in the prescribing dataset (4.10.3 Opioid 
dependence).  BNF codes in the prescribing dataset were also used to identify unipolar mood 
disorders (4.3 Antidepressant drugs), bipolar disorder (4.2.3 Drugs for mania and 
hypomania), anxiety disorders (4.1.2 Anxiolytics), sleep disorders (4.1.1 Hypnotics) and 
psychotic disorders (4.2.1 Antipsychotic drugs and 4.2.2 Antipsychotic depot injections).  
The receipt of pain treatment in secondary care was identified using the SMR00 (treatment at 
specialist pain services).  However, it is important to note that chronic pain may be managed 
in other specialist settings (such as rheumatology), but it does indicate the use of secondary 
care pain services.  The data did not permit the identification of non-pharmaceutical 
interventions for the treatment of pain. 
Reasons for attendance at the ED were ascertained using the ‘Diagnosis Code’ field 
contained within the ED dataset.  These data are recorded, at the time of attendance, as high-
level codes, indicating the specialty of the presenting complaint.  Data were extracted for 




































































injury’); cardiovascular disease (’03 cardiovascular’); respiratory disease (’17 respiratory’); 
gastrointestinal disorders (’08 gastrointestinal’); endocrine/metabolic disorders (’06 
endocrine/metabolic’); substance use disorder (’02 alcohol and/or substance use problems’); 
and psychiatric disorders (‘16 psychiatry’).  There was no diagnostic code that would cover 
all chronic pain. 
Equianalgesic computations were made only for opioid medication.  Morphine-
equivalent doses were established using an online equianalgesic calculator based on the 
American Pain Society guidelines and critical review papers focusing on the issue of 
equianalgesic dosing (http://clincalc.com/opioids/).  The morphine-equivalent dose for each 
of the opioid medications from the present study is reported in the supplementary digital 
content (Tables S2 and S3). 
 ‘Strong’ and ‘weak’ opioids were identified using the Analgesic Ladder compiled by 
the World Health Organization (WHO).  Overall dose increases and decreases were identified 
by calculating each participant’s mean dose during the first 3 months of the 12-month 
observation period and comparing that value with the mean of the final 9 months.  A 
transition from opioid to non-opioid analgesics, and vice versa, was indicated where the 
cessation or initiation of opioid analgesic treatment occurred at any point during the 
observation period.  No participants transitioned twice during this time, so the groups were 
mutually exclusive. 
The data were hosted, linked and pseudo-anonymised within HIC Services.  Since 
each of the datasets included in the present study comprised data pertaining to NHS events, 
all datasets included NHS CHI numbers for all individuals present in these datasets.  HIC 
Services used the CHI numbers from the study sample (obtained from the CHI dataset) to 
identify all relevant individuals and extract all relevant data from the health datasets included 




































































Following linkage and the extraction of all relevant data, CHI numbers were replaced by 
proxy CHI (proCHI) numbers in the final release, with the key being retained securely within 
HIC Services.  The reseach team was then able to track events for individuals across all data 
extracts using the pseudo-anonymised proCHI identifier.  Data were analysed within the HIC 
Safe Haven, which was accessed via a secure web link, and outputs were scrutinised to 
ensure data security prior to release to the research team. 
 
Statistical considerations 
Data were analysed using the Statistical Package for Social Sciences (SPSS; v22).  
The chi square test was used in the analysis of categorical dependent variables by categorical 
independent variables.  Statistical findings were reported as chi-square value and degrees of 
freedom (χ2(df)), probability value (p) and effect size, Pearson’s Phi or Cramer’s V (ω).  
Pearson’s Phi was used to assess the effect size in 2x2 contingency tables and Cramer’s V 
was used where there were more than two levels in independent variables.  Descriptive 
summary data were presented as number of participants (n) and percentage of group (%). 
Univariate analysis of variance (ANOVA) was used to assess continuous dependent 
variables by categorical independent variables.  Statistical findings of the univariate ANOVA 
were reported as F value, between-subjects degrees of freedom and within-subjects degrees 
of freedom (F(between-subjects df, within-subjects df)), probability value (p) and effect size, 
partial eta squared (
2
p ).  Descriptive summary data were presented as mean value (
_
x ) and 
standard deviation around the mean (σ). 
Binary logistic regression was used to assess the independent predictive capacity of 
categorical and continuous predictor variables on binary target variables.  Tables show 







































































Ethical approval was not specifically required for the present study, since all data 
were pseudo-anonymised and accessed via a national Safe Haven; however, a favourable 
ethical opinion was obtained from the East of Scotland Research Ethics Committee 




An examination of the study population revealed that there was a higher proportion of 
males (73%, n=2668) than females (27%, n=996).  Figure 1 shows the distribution of age 
and deprivation status in the study population compared with the general population of 
Scotland. 
 
[Insert Figure 1 around here] 
 
Figure 1a shows that there was a higher proportion of those aged 30-49 years in the 
study cohort compared with the general population of Scotland.  Consequently, there were 
lower proportions of those aged 20-29 years and 60+ years.  Figure 1b shows that there was 
a higher proportion of deprived (quintiles 1-2) individuals and a lower proportion of affluent 
(quintiles 3-5) individuals than would be found in the general population. 
A breakdown of the numbers in each group having attended the ED during the 12-
month observation period is shown in Figure 2.  This includes attendance by patients with 
chronic, painful conditions (as defined by analgesic prescribing) and those with chronic pain 





































































[Insert Figure 2 around here] 
 
Figure 2 shows that, of the 368 participants identified as having chronic pain, 68.5% 
(n=252) had attended the ED for any reason on at least one occasion during the observation 
period, and 32.3% (n=119) had attended for CMP management.  Figure 3 shows the 
proportion of those with and without chronic pain who attended the ED for any reason on at 
least one occasion during the observation period, and it describes presenting complaint in 
those with chronic pain who attended the ED. 
 
[Insert Figure 3 around here] 
 
Figure 3a shows that, compared with those with no pain, a significantly higher 
proportion of those with chronic pain attended the ED for any reason on at least one occasion 
during the observation period (χ2(1)=219; p<0.001; ω=0.244).  Figure 3b shows that almost 
half of those with chronic pain who attended the ED attended for CMP management.  A 
further 28 participants with chronic pain attended the cardiovascular and gastrointestinal 
specialties: these participants could have been seeking treatment for chronic pain but there 
was insufficient clinical information contained within the dataset to determine specific 
reasons for attendance.  Figure 4 shows analgesic prescribing characteristics in those with 
chronic pain who did and did not attend the ED during the observation period. 
 





































































Figure 4 shows that around a quarter of those in receipt of prescribed analgesics were 
prescribed opioids, and there was little difference in this pattern between groups.  There was 
no group difference in mean oral morphine-equivalent daily dose (oMEDD) between those 
that attended and did not attend the ED.  Analgesic prescriptions were issued for a mean 
duration of around 6 months during the observation period, and there was little difference 
between groups.  It should be noted that this figure refers to the issue of analgesic 
prescriptions during the 12-month observation period, and that data were not available to 
facilitate estimates of the length of time in receipt of analgesic prescriptions outside of the 
observation period. 
 
Risk of emergency department attendance for chronic musculoskeletal pain management 
Table 1 shows the sociodemographic characteristics, analgesic treatment 
characteristics and medical and psychiatric morbidities associated with risk of attendance at 
the ED for CMP management.  Only 3.0% (n=7) of participants were diagnosed with 
malignant disease and 1.3% (n=3) had their pain problems treated in a specialist pain service.  
Due to low numbers, these variables were not included in the analyses. 
 
[Insert Table 1 around here] 
 
Table 1 shows that a significantly higher proportion of those that attended for the 
treatment of CMP was male and relatively socioeconomically affluent.  In consequence, the 
remainder of the analyses were adjusted for gender and deprivation status.  The adjusted odds 
ratios show that being prescribed strong opioids, transitioning from non-opioid to opioid 
analgesics and recent analgesic dose increases were each independently protective of ED 




































































transitioning from opioid to non-opioid analgesics were predictive of ED attendance in this 
group.  Furthermore, there were no associations with medical morbidity, but being in receipt 
of prescribed antidepressants (specifically tricyclics), benzodiazepines and hypnotics for the 
treatment of psychiatric disorders were independently protective of ED attendance for CMP 
management. 
 
Relative cost of emergency department treatment for chronic pain management 
All ED attendances (n=1,219) were included in calculating the cost of ED treatment 
for CMP relative to that of other clinically-significant morbidities.  This included participants 
with chronic pain (n=252) and without chronic pain (n=967).  Findings are shown in Table 2. 
 
[Insert Table 2 around here] 
 
Table 2 shows that more patients attended the ED for the treatment of CMP than for 
any other clinically-significant medical condition, and that this was one of the most expensive 
conditions overall to treat, second only to that of cardiovascular disease.  Based on a Scottish 
population estimate of 5.42 million and the figures in the present study, more than 174,000 
patients are likely to seek treatment for CMP management across Scotland in any 12-month 
period, with ED costs for the treatment of this condition likely to amount to around £26 
million (~$33 million). 
 
DISCUSSION 
More than two thirds of those identified with CP attended the ED for any problem 
during the observation period, with almost a half of these attending for CMP management.  A 




































































socioeconomically affluent.  Being in receipt of prescribed strong opioid analgesics, 
transitioning from non-opioid to opioid analgesics and recent analgesic dose increases were 
each independently protective of ED attendance for CMP management.  Conversely, recent 
analgesic dose decreases and transitioning from opioid to non-opioid analgesics were 
predictive of ED attendance.  Being in receipt of prescribed tricyclic antidepressants, 
benzodiazepines and hypnotics were independently protective of ED attendance for CMP 
management.  More patients attended the ED with CMP than with any other medical 
condition, and this was one of the most expensive conditions overall to treat.  Projected 
estimates suggest that almost 175,000 patients are likely to seek treatment for CMP across 
Scotland (population = 5.42M million) in any 12-month period, with ED costs for the 
treatment of this condition likely to amount to around £26 million (~$33 million). 
As a result of data collection processes across Scottish EDs, it is not currently 
possible to identify all attendances for CP management.  As discussed, the present study used 
the best available surrogate indicator – painful musculoskeletal conditions (excluding injury); 
however, this fails to encompass important conditions, such as abdominal and pelvic pain, 
and some presentations may have been for relatively short-term problems (although in people 
already identified with CP).  In an examination of all loci of pain in 5,279 patients with CP in 
the UK [913], 7443 specific sites of pain were reported.  Most loci were suggestive of 
musculoskeletal pain (89%); however, there was also a substantial prevalence of abdominal 
(8%) and pelvic (3%) pain.  In consequence, the prevalence and costs reported in this article 
are likely to be an underestimate of the true burden of CP placed upon ED resources. 
Whilst CP is more prevalent in females than males [8,17,26,48,55,57], the present 
study found that male gender was a risk factor for ED attendance for CMP.  A higher 
prevalence of chronic pain is often reported in females [12,27,37,66,73,75], and females are 




































































previous study examining all-cause ED attendance [2], the present study found that male 
gender was a significant risk factor for ED attendance for unmanageable pain.  Men are 
reported to be twice as likely as women to have inadequate health literacy [76].  Furthermore, 
men have been shown to be less likely to seek medical assistance from general practitioners 
[1,23,35,78], pharmacists [56] and pain services specifically [10,22,45] when they are ill.  It 
may be the case that men are relatively reluctant to seek medical assistance prior to reaching 
crisis stage; indeed, Juel and Christensen [43] suggested a link between men’s lower use of 
primary care and higher use of hospital services in their analysis of 35.8 million general 
practitioner attendances and 1.2 million hospitalisations in Denmark during 2005.  Our data, 
however, do not allow a definitive explanation for this finding.  All-cause ED attendance is 
reported to be most common in socioeconomically deprived individuals [6,31,49].  However, 
similar to the findings of Poulin and colleagues [46], the present study found that 
socioeconomic affluence was a risk factor for ED attendance specifically for CMP 
management.  A higher proportion of males and affluent individuals may be more likely to be 
in full-time employment thus finding it harder to attend a GP practice during working hours; 
indeed, Zhou and colleagues [64] found that the inability to get to an in-hours GP 
appointment was associated with higher use of out-of-hours healthcare services.ED 
attendance for any complaint is reported to be most common in socioeconomically deprived 
individuals [9,46,67], and these individuals have been shown to demonstrate a preference for 
hospital treatment compared with primary care [44].  However, similar to the findings of 
Poulin and colleagues [64], the present study found that relative socioeconomic affluence was 
a risk factor for ED attendance specifically for acute exacerbation of chronic pain.  Joynt and 
colleagues [42] found that patients from the highest socioeconomic quartile were more likely 
to receive opioid analgesics on presentation at EDs compared with those from the lowest 




































































based on previous experience of not having received immediate pain relief.  However, it is 
impossible to interpret this finding without further research. 
Whilst prescription opioids are associated with increased overdose risk 
[1217,5674,6080] and high doses are associated with ED attendance for alcohol- and drug-
related problems [47], the present study found that opioid (compared with non-opioid) 
analgesics and higher doses were protective of ED attendance for CMP management.  
Furthermore, recent opioid analgesic dose reductions and transitioning from opioid to non-
opioid analgesics were risk factors for ED presentation with CMP.  An understanding of the 
potential adverse effects of opioid tapering in patients with CP is yet to be achieved, as 
highlighted in a recent systematic review of the topic [3550].  However, one study [3651] 
found that, following analgesic opioid tapering and eventual discontinuation in patients with 
CNCP, 49% of their 494 participants experienced an opioid-related hospitalisation or ED 
attendance as a result of overdose or other problems associated with problematic use.  As 
with our present study, these findings echo a recent Food and Drug Administration (FDA) 
safety announcement concerning potential ‘serious harm’ associated with rapid tapering or 
discontinuation of opioid analgesics, such as withdrawal symptoms, uncontrolled pain, 
psychological distress and suicide [2232].  Whilst there are potential risks associated with 
opioid prescribing, the findings of this study suggest that adequate pain management may 
help to stabilise pain problems in patients with CP and reduce the need for ED intervention, 
and that opioid tapering or discontinuation should not be implemented in the absence of an 
alternative pain management plan and careful monitoring of potential adverse effects. 
Being in receipt of prescribed tricyclic antidepressants (but not selective serotonin 
reuptake inhibitors (SSRIs)), benzodiazepines and/or hypnotics for the management of 
psychiatric disorders was independently protective of ED attendance for CMP management.  




































































commonly used in the treatment of chronic neuropathic pain 
[1[3,1318,1929,2030,3954,4765]; whereas, SSRIs are ineffective in CP management 
[1[3,1015,1929,2030].  Furthermore, a recent systematic review of randomized control trials 
[3348] highlighted the effectiveness of TCAs in treating insomnia.  Insomnia is shown to 
exacerbate pain problems [1828,3247,50], and the potential therapeutic effect of TCAs on 
insomnia may account for the protective effect on ED attendances for CMP in a portion of 
patients with CP. 
Clinical insomnia and anxiety disorders are more prevalent in individuals with CP 
than in pain-free controls [4260,5169,5877].  Pain is now widely understood as a 
multidimensional construct featuring a strong emotional component in addition to sensory 
experiences [2940], and pain problems are shown to be exacerbated by both anxiety 
[2536,6383] and insomnia [1828,3247,5068].  Our findings that benzodiazepine or hypnotic 
use reduced ED attendance for CMP may relate to the central effects of these agents, with a 
possible decrease in anxiety (or insomnia), although these agents are recommended only for 
short term use.  Furthermore, there are serious risks associated with the concomitant use of 
opioids and central nervous system depressants, which can ultimately result in premature 
mortality due to respiratory depression [1419,3041,4057,4361].  There is a need for further 
studies examining non-pharmaceutical interventions for the treatment of anxiety disorders 
and insomnia in patients with CMP to ensure safe and effective clinical practice. 
To the authors’ knowledge, this is the first study to examine the burden that CMP 
places upon EDs.  CMP was the second most resource-intensive medical condition to treat in 
the ED, despite previous findings suggesting that CP is not most effectively managed by 
emergency services [24,5270,6181,6282].  Indeed, this finding further supports the proposal 
that effective community-based pain management could alleviate some of the pressure placed 




































































effective as analgesic pain management for patients who require opioid tapering.  The 
projected national cost estimates presented here require validation in national studies, and 
further research is required to understand patients’ motives for, and expectations of, 
presentation at EDs with CMP.  Only through the proposed further research can cost-effective 
pain management policy be developed which could deliver effective treatment to those with 
CMP, thereby improving overall quality of life. 
 
Limitations 
The study cohort was characterised by a relatively high proportion of males and a 
lower proportion of those aged 60+ years compared with the Scottish population as a whole, 
and this may have resulted in an underestimation of pain prevalence and treatment costs 
[1625].  Conversely, the relatively high proportion of socioeconomically deprived individuals 
may have resulted in an overestimation of these figures due to the poorer health associated 
with these socioeconomic groups [1520].  A key limitation of the present study is that the 
identification of participants with CP was based on community-dispensed analgesic 
prescribing for at least 3 consecutive months within the observation period;, and this, 
therefore, this did not include individuals who were treated only with non-pharmaceutical 
interventions or over-the-counter (OTC) medication, and it may have resulted in the 
exclusion of some individuals who had been hospitalised during the observation period or 
had migrated to the area relatively recently.  In consequence, the findings of the present study 
are likely to be an underestimation of the numbers attending the ED with CP and the total 
cost of treatment.  The principal limitation in estimating the burden of CP on ED resources is 
that, due to the nature of ED data coding, it is not currently possible to identify all 
attendances for CP.  Attendance for CMP was considered the most appropriate surrogate 




































































clinic activity) is known to provide underestimates of the number of patients attending 
specialist pain services, which may account for the insufficient numbers in the present study 
to enable statistical testing.  It should be noted that patients may have their CP treated in other 
specialist services (such as orthopaedics or neurology) but that administrative datasets do not 
provide sufficient clinical information to identify these patients.  Finally, psychometric 
assessment of the process of assigning BNF codes (indicating intention to treat) in the 
prescribing dataset could strengthen research using these data. 
 
Conclusions 
All-cause ED attendance was significantly higher in those with CP compared with 
those with no evident pain.  More patients attended the ED for the treatment of CMP than for 
any other medical condition, and this was one of the most expensive conditions to treat, 
second only to cardiovascular disease.  We have identified some sociodemographic and 
treatment-related factors associated with the rates of attendance that need to be considered 
with circumspection.  There is a need to identify effective, community-based, non-
pharmacological interventions to ensure safe treatment practices for patients with CMP and to 
help to reduce the need for ED interventions in the management of this chronic condition.  
Further research is needed to understand the factors that drive treatment-seeking behaviour, 
such as ED attendance, for CMP management. 
 
ACKNOWLEDGEMENTS 
There are no financial or other acknowledgements to be made.  The authors have no conflicts 
of interest to disclose. 
 




































































In accordance with the information governance policies of the data gatekeepers, the data used 
in the present analyses are not available for sharing. 
 
REFERENCES 
[1] Addis ME, Mahalik JR. Men, masculinity, and the contexts of help seeking, Am Psychol 
2003;58:1:5–14. 
 
[2] Anson O, Carmel S, Levin M. Gender differences in the utilization of emergency 
department services. Women Health 1991;17(2):91-104. 
 
[13] Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T. EFNS 
guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 
2010;17:1113–1123. 
 
[24] Baker K. Chronic pain syndromes in the emergency department: identifying guidelines 
for management. Emerg Med Australas 2005;17(1):57–64. 
 
[5] Bertakis KD, Azari R, Helms LJ, Callahan EJ, Robbins JA. Gender differences in the 
utilization of health care services. Fam Pract 2000;49(2):147–152. 
 






































































[47] Braden JB, Russo J, Fan M-Y, Edlund MJ, Martin BC, De Vries A, Sullivan MD. 
Emergency department visits among recipients of chronic opioid therapy. Arch Intern Med 
2010;170(16):1425-1432. 
 
[58] Chen E, Tsoy D, Upadhye S, Chan TM. The Acute Care of Chronic Pain Study: 
perceptions of acute care providers on chronic pain, a social media-based Investigation. 
Cureus 2018;10(3):e2399. 
 
[69] Cookson R, Propper C, Asaria M ,Raine R. Socio‐economic inequalities in health care in 
England. Fisc Stud 2016;37(3–4):371–403. 
 
[10] Cornally N, McCarthy G. Chronic pain: the help-seeking behavior, attitudes, and beliefs 
of older adults living in the community. Pain Manag Nurs 2011;12:206–17. 
 
[711] Crawford K, Morphet J, Jones T, Innes K, Griffiths D, Williams A. Initiatives to reduce 
overcrowding and access block in Australian emergency departments: a literature review. 
Collegian 2014;21(4):359-366. 
 
[812] Dao TT, LeResche L. Gender differences in pain. J Orofac Pain 2000;14:169–184. 
 
[913] Davies HTO, Crombie IK, Macrae WA. Where does it hurt? Describing the body 





































































[14] Desai N, Shah P. High burden of hospital resource utilization in patients with 
hidradenitis suppurativa in England: a retrospective cohort study using hospital episode 
statistics. Br J Dermatol 2017;176(4):1048-1055. 
 
[1015] Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: a 
review. J Clin Pharmacol 2012;52:6-17. 
 
[1116] Du S, Yuan C, Xiao X, Chu J, Qiu Y, Qian H. Self-management programs for chronic 
musculoskeletal pain conditions: a systematic review and meta-analysis. Patient Educ Couns 
2011;85(3):e299-310. 
 
[1217] Dunn KN, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, 
Weisner CM, Silverberg MJ, Campbell CI, Psaty BM, Von Korff M. Opioid prescriptions for 
chronic pain and overdose: a cohort study. Ann Intern Med 2010;152(2):85-92. 
 
[1318] Dworkin RH, O’Connor B, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso 
EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, 
Turk DC, Wallace MS. Pharmacologic management of neuropathic pain: evidence-based 
recommendations. Pain 2007;132:237–251. 
 
[1419] Ekström MP, Bornefalk-Hermansson A, Abernethy AP, Currow DC. Safety of 






































































[1520] Elliott AM, Smith BH, K Penny KI, Smith WC, Chambers WA. The Epidemiology of 
Chronic Pain in the Community. Lancet 1999;354(9186):1248-52. 
 
[21] Elliott J, Jacques RM, Kruger J, Campbell MJ, Amiel SA, Mansell P, Speight J, Brennan 
A, Heller SR. Substantial reductions in the number of diabetic ketoacidosis and severe 
hypoglycaemia episodes requiring emergency treatment lead to reduced costs after structured 
education in adults with Type 1 diabetes. Diabet Med 2014;31(7):847-853. 
 
[22] Eriksen J, Sjogren P, Ekholm O, Rasmussen NK. Health care utilisation among 
individuals reporting long-term pain: an epidemiological study based on Danish National 
Health Surveys. Eur J Pain 2004;8:517–23. 
 
[23] European Commission. The state of men’s health in Europe—extended report. Brussels: 
European Union, 2011. 
 
[24] Farmer AJ, Brockbank KJ, Keech ML, England EJ, Deakin CS. Incidence and costs of 
severe hypoglycaemia requiring attendance by the emergency medical services in South 
Central England. Diabet Med 2012;29(11):1447-1450. 
 
[1625] Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain 
in the UK: a systematic review and meta-analysis of population studies. BMJ Open 
2016;6:e010364. 
 
[26] Fielding S, Porteous T, Ferguson J, Maskrey V, Blyth A, Paudyal V, Barton G, Holland 




































































practices and emergency departments through retrospective review of routine data in North 
East Scotland. Fam Pract 2015;32(2):165-172. 
 
[1727] Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL, 3rd. Sex, 
gender, and pain: a review of recent clinical and experimental findings. J Pain 2009;10:447–
485. 
 
[1828] Finan PH, Goodin BR, Smith MT. The association of sleep and pain: an update and a 
path forward. J Pain 2013;14(12):1539–1552. 
 
[1929] Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, 
Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, 
Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic 
pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162–173. 
 
[2030] Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of 
neuropathic pain. Pain 2010;150:573–581. 
 
[2131] Flowerdew L, Brown R, Russ S, Vincent C, Woloshynowych M. Teams under 
pressure in the emergency department: an interview study. Emerg Med J 2012;29:e2. 
 
[2232] Food and Drug Administration (2019). FDA identifies harm reported from sudden 
discontinuation of opioid pain medicines and requires label changes to guide prescribers on 







































































[2333] GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, 
regional, and national incidence, prevalence, and years lived with disability for 354 diseases 
and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global 
Burden of Disease Study 2017. Lancet 2018;392(10159): 1789–1858. 
 
[2434] Graham CA. Emergency care systems: increasing pressures but little sustainability. 
Eur J Emerg Med 2017;24(3):157. 
 
[35] Green CA, Pope CR. Gender, psychosocial factors and the use of medical services: a 
longitudinal analysis. Soc Sci Med 1999;48:1363–72. 
 
[2536] Gureje O. Comorbidity of pain and anxiety disorders. Curr Psychiatry Rep 
2008;10:318–322. 
 
[2637] Hardt J, Jacobsen C, Goldberg J, Nickel R, Buchwald D. Prevalence of chronic pain in 
a representative sample in the United States. Pain Med 2008;9:803–812. 
 
[2738] He J, Hou X-Y, Toloo S, Patrick JR, FitzGerald G. Demand for hospital emergency 
departments: a conceptual understanding. World J Emerg Med 2011; 2(4): 253–261. 
 
[2839] Hsia RY, Nath JB, Baker LC. California emergency department visit rates for medical 





































































[2940] IASP. Task force on taxonomy of the international association for the study of pain. 
In: Merskey H, Bogduk N, editors. Descriptions of Chronic Pain Syndromes and Definitions 
of Pain Terms. Seattle, Wash, USA: IASP Press, 1994. 
 
[3041] Jones CM, McAninch JK. Emergency department visits and overdose deaths from 
combined use of opioids and benzodiazepines. Am J Prev Med 2015;49(4):493-501. 
 
[42] Joynt M, Train MK, Robbins BW, Halterman JS, Caiola E, Fortuna RJ. The impact of 
neighborhood socioeconomic status and race on the prescribing of opioids in emergency 
departments throughout the United States. J Gen Intern Med 2013;28(12):1604-10. 
 
[43] Juel K, Christensen K. Are men seeking medical advice too late? Contacts to general 
practitioners and hospital admissions in Denmark 2005. J Public Health 2008;30(1):111–113, 
 
[44] Kangovi S, Barg FK, Carter T, Long JA, Shannon R, Grande D. Understanding why 
patients of low socioeconomic status prefer hospitals over ambulatory care. Health Aff 
(Millwood) 2013;32(7):1196-203. 
 
[45] Kaur S, Stechuchak KM, Coffman CJ, Allen KD, Bastian LA. Gender differences in 
health care utilization among veterans with chronic pain. J Gen Intern Med 2007;22:228–33. 
 
[3146] Khan Y, Glazier RH, Moineddin R, Schull KN. A population-based study of the 
association between socioeconomic status and emergency department utilization in Ontario, 





































































[3247] Kundermann B, Krieg JC, Schreiber W, Lautenbacher S. The effects of sleep 
deprivation on pain. Pain Res Manag 2004;9(1):25-32. 
 
[3348] Liu Y, Xu X, Dong M, Jia S, Wei Y. Treatment of insomnia with tricyclic 
antidepressants: a meta-analysis of polysomnographic randomized controlled trials. Sleep 
Mede 2017;34:126-133. 
 
[3449] Lowthian JA, Curtis AJ, Cameron PA, et al Systematic review of trends in emergency 
department attendances: an Australian perspective. Emerg Med J 2011;28:373-377. 
 
[3550] Mackey K, Anderson J, Bourne D, Chen E, Peterson K. Evidence Brief: Benefits and 
Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic 
Pain. Washington, DC: Evidence Synthesis Program, Health Services Research and 
Development Service, Office of Research and Development, Department of Veterans Affairs. 
VA ESP Project #09-199; 2019. 
 
[3651] Mark TL, Parish W. Opioid Medication Discontinuation and risk of adverse opioid-
related health care events. J Subst Abuse Treat 2019;103:58-63. 
 
[3752] Mason S, Mountain G, Turner J, Arain M, Revue E, Weber EJ. Innovations to reduce 






































































[3853] Massimi A, De Vito C, Brufola I, Corsaro A, Marzuillo C, Migliara G, Rega ML, 
Ricciardi W, Villari P, Damiani G. Are community-based nurse-led self-management support 
interventions effective in chronic patients? Results of a systematic review and meta-analysis. 
PLoS One 2017;12(3):e0173617. 
 
[3954] Micó JA, Ardid D, Berrocoso E, Eschalier A (2006) Antidepressants and pain. Trends 
in Pharmacol Sci 2006;27(7):348-354. 
 
[55] Milani SA, Crooke H, Cottler LB, Striley CW. (2016). Sex differences in frequent ED 
use among those with multimorbid chronic diseases. Am J Emerg Med 2016;34(11):2127–
2131. 
 





[4057] Nielsen S, Dietze P, Lee N, Dunlop A, Taylor D. Concurrent buprenorphine and 
benzodiazepines use and self‐reported opioid toxicity in opioid substitution treatment. 
Addiction 2007;102(4):616-622. 
 
[4158] Palmer KT, Harris EC, Linaker C, Barker M, Lawrence W, Cooper C, Coggon D. 
Effectiveness of community- and workplace-based interventions to manage musculoskeletal-





































































[59] Parkinson K, Newbury-Birch D, Phillipson A, Hindmarch P, Kaner E, Stamp E, Vale L, 
Wright J, Connolly J. Prevalence of alcohol related attendance at an inner city emergency 
department and its impact: a dual prospective and retrospective cohort study. Emerg Med J 
2016;33(3):187-193. 
 
[4260] Pereira FG, França MH, Paiva MCA, Andrade LH, Viana MC. Prevalence and clinical 
profile of chronic pain and its association with mental disorders. Rev Saude Publica 
2017;51:96. 
 
[4361] Pergolizzi JV, LeQuang JA. Reappraising the use of benzodiazepines in chronic pain 
patients. Postgrad Med 2020;6:1-3. 
 
[4462] Portenoy RK, Bennett DS, Rauck R, Simon S, Taylor D, Brennan M, Shoemaker S. 
Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic 
noncancer pain. J Pain 2006;7(8):583-91. 
 
[4563] Potier T, Tims E, Kilbride C, Rantell K. Evaluation of an evidence based quality 
improvement innovation for patients with musculoskeletal low back pain in an accident and 
emergency setting. BMJ Qual Improv Rep 2015;4(1):u205903.w2411. 
 
[4664] Poulin PA, Nelli J, Tremblay S, Small R, Caluyong MB, Freeman J, Romanow H, 
Stokes Y, Carpino T, Carson A, Shergill Y, Stiell IG, Taljaard M, Nathan H, Smyth CE. 
Chronic pain in the emergency department: a pilot mixed-methods cross-sectional study 






































































[4765] Rodieux F, Piguet V, Berney P, Desmeules J, Besson M. Pharmacogenetics and 
analgesic effects of antidepressants in chronic pain management. Per Med 2015;12(2):163-
175. 
 
[4866] Rollman GB, Lautenbacher S. Sex differences in musculoskeletal pain. Clin J Pain 
2001;17:20–24. 
 
[4967] Shah SM, Cook DG. Socio-economic determinants of casualty and NHS Direct use. J 
Public Health (Oxf) 2008;30(1):75–81. 
 
[5068] Tang NKY. Insomnia co-occurring with chronic pain: clinical features, interaction, 
assessments and possible interventions. Rev Pain 2008;2(1):2–7. 
 
[5169] Tang NKY, Wright KJ, Salkovskis PM. Prevalence and correlates of clinical insomnia 
co-occurring with chronic back pain. J Sleep Res 2007;16:85–95. 
 
[5270] Todd KH, Cowan P, Kelly N, Homel P. Chronic or recurrent pain in the emergency 
department: national telephone survey of patient experience. West J Emerg Med 
2010;11(5):408–415. 
 
[5371] Todd KH, Ducharme J, Choiniere M, Johnson C, Crandall C, Puntillo K. Pain and 
pain-related functional interference among discharged emergency department patients. Ann 





































































[5472] United States Bone and Joint Initiative. Prevalence, Societal and Economic Cost. 
Third edition. Illinois: The Burden of Musculoskeletal Diseases in the United States; 2016. 
http://www.boneandjointburden.org 
 
[5573] Unruh AM. Gender variations in clinical pain experience. Pain 1996;65:123–167. 
 
[5674] Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies — tackling 
the opioid-overdose epidemic. N Engl J Med 2014;370:2063-2066. 
 
[5775] Von Korff M, Dworkin SF, Le Resche L, Kruger A. An epidemiologic comparison of 
pain complaints. Pain 1988;32:173–183. 
 
[76] von Wagner C, Knight K, Steptoe A, Wardle J. Functional health literacy and health-
promoting behaviour in a national sample of British adults. J Epidemiol Commun H 
2007;61:1086-1090. 
 
[5877] Vun E, Turner S, Sareen J, Mota N, Afifi TO, El-Gabalawy R. Prevalence of 
comorbid chronic pain and mental health conditions in Canadian Armed Forces active 
personnel: analysis of a cross-sectional survey. CMAJ Open 2018;6(4):E528–E536. 
 
[78] Wang Y, Hunt K, Nazareth I, Freemantle N, Petersen I. Do men consult less than 






































































[5979] Weaver RG, Manns BJ, Tonelli M, Sanmartin C, Campbell DJ, Ronksley PE, 
Lewanczuk R, Braun TC, Hennessy D, Hemmelgarn BR. Access to primary care and other 
health care use among western Canadians with chronic conditions: a population-based 
survey. CMAJ Open 2014;2(1):E27–E34. 
 
[6080] Wilder C, Miller SC, Tiffany E, Winhusen T, Winstanley EL, Stein MD. Risk factors 
for opioid overdose and awareness of overdose risk among veterans prescribed chronic 
opioids for addiction or pain. J Addic Dis 2016;35(1):42-51. 
 
[6181] Wilsey BL, Fishman SM, Tsodikov A, Ogden C, Symreng I, Ernst A. Psychological 
comorbidities predicting prescription opioid abuse among patients in chronic pain presenting 
to the emergency department. Pain Med 2008;9(8):1107–1117. 
 
[6282] Wilsey BL, Fishman SM, Crandall M, Casamalhuapa C, Bertakis KD. A qualitative 
study of the barriers to chronic pain management in the ED. Am J Emerg Med 
2008;26(3):255–263. 
 
[6383] Woo AK. Depression and anxiety in pain. Rev Pain 2010;4(1):8–12. 
 
[64] Zhou Y, Abel G, Warren F, Roland M, Campbell J, Lyratzopoulos G. Do difficulties in 
accessing in-hours primary care predict higher use of out-of-hours GP services? Evidence 







































































Figure 1: a. Distribution of age in the study cohort (percentages) compared with the 
distribution in the general Scottish population; and b. distribution of Scottish Index of 
Multiple Deprivation (SIMD) quintiles in the study population compared with the equal 
distribution (denoted by a horizontal line) found in the general population 





Figure 2: Breakdown of cohort by presence or absence of chronic pain and attendance at 
emergency departments 
 
Figure 3: a. Proportions with chronic pain and no pain attending the emergency department 
for any reason on at least one occasion during the observation period; and b. presenting 
complaint in those with chronic pain who attended the emergency department 
 
Figure 4: Analgesic prescribing characteristics in those with chronic pain who did and did 
not attend the emergency department during the observation period (a. percentage of 
participants in receipt of prescribed opioid analgesics; b. mean oral morphine-equivalent 
daily dose (mg) per patient over the 12-month observation period of those who were in 
receipt of prescribed opioid analgesics; c. mean months duration in receipt of any analgesic 




































































Emergency department attendance was higher in those with than without chronic pain.  Risk factors 
















































































































































































































































Table 1: Sociodemographic characteristics, analgesic treatment characteristics and 
psychiatric morbidity in those with chronic pain who attended the emergency department for 
the treatment of CMP in 2014 (n=119) compared with those with chronic pain who did not 
attend the emergency department (n=116) 
Predictor Reference OR ORadj 95% CI 
Sociodemographic characteristics 
Male Female 2.21 ----- 0.26-3.89 
Age Each 1-year increase 0.99 ----- 0.97-1.01 
Socioeconomically affluent Relatively deprived 2.06 ----- 1.21-3.51 
Rural habitation Urban habitation 1.76 ----- 0.94-3.27 
     
Analgesic treatment characteristics 
Opioid analgesics Non-opioid analgesic 0.78 0.77 0.38-1.55 
Strong opioids Weak opioids 0.18 0.21 0.05-0.89 
Opioid to non-opioid No change in class 5.39 5.08 1.42-18.16 
Non-opioid to opioid No change in class 0.23 0.25 0.07-0.94 
Increase in analgesic dose No change in dose 0.25 0.24 0.11-0.53 
Decrease in analgesic dose No change in dose 4.50 4.55 1.75-11.83 
     
Treatment for medical morbidity 
Gastrointestinal (GI) 
disorders 
No GI disorders 0.62 0.68 0.35-1.34 
Cardiovascular (CV) 
disease 
No CV disease 0.86 1.67 0.85-3.28 
Respiratory disorders No respiratory disorders 0.74 0.86 0.45-1.61 
Endocrine disorders No endocrine disorders 0.58 0.66 0.34-1.26 
     
Treatment for psychiatric morbidity 
Opioid agonist therapy * No mental illness ** 1.36 1.64 0.95-2.85 
Antidepressants No mental illness ** 0.39 0.54 0.29-0.99 
Table 1
     Tricyclic treatment † SSRI treatment 0.10 0.10 0.04-0.25 
Benzodiazepines ‡ No mental illness ** 0.34 0.46 0.21-0.98 
Hypnotics No mental illness ** 0.34 0.45 0.20-1.00 
Antipsychotics No mental illness ** 0.26 0.36 0.08-1.62 
ORadj shows ORs adjusted for gender and deprivation status 
* All of these participants were treated with methadone hydrochloride 
† All participants that were prescribed antidepressant medication were in receipt of either selective 
serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs) – no participants were in 
receipt of monoamine oxidase inhibitors (MAOIs) or other antidepressant medication 
‡ All sedatives were included; however, all of these participants were prescribed benzodiazepines, 
almost exclusively diazepam 
** No psychotropic prescribing or attendance at specialist psychiatric services during 2014 
 
Table 2: Cost of emergency department treatment for clinically-significant medical 
conditions in the study cohort and estimated national cost based on these figures and a 
Scottish population estimate of 5.42 million 




 n £cost ($) N £cost ($) 
Cardiovascular disease 100 20,410 (26,168) 146,340 29.87m (38.30m) 
Chronic musculoskeletal pain 119 17,680 (22,668) 174,524 25.93m (33.24m) 
Respiratory disease 45 12,740 (16,334) 66,124 18.72m (24.00m) 
Gastrointestinal disorders 62 12,090 (15,501) 91,056 17.76m (22.77m) 
Endocrine/metabolic disorders 25 6,110 (7,834) 36,856 9.01m (11.55m) 
Substance use disorder 15 2,080 (2,667) 22,222 3.08m (3.95m) 
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